Literature DB >> 16649995

The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity.

Kenji Masuda1, Kenzo Sakamoto, Miki Kojima, Takahide Aburatani, Takuya Ueda, Hiroshi Ueda.   

Abstract

While many antibodies with strong antigen-binding affinity have stable variable regions with a strong antibody heavy chain variable region fragment (V(H))/antibody light chain variable region fragment (V(L)) interaction, the anti-lysozyme IgG HyHEL-10 has a fairly strong affinity, yet a very weak V(H)/V(L) interaction strength, in the absence of antigen. To investigate the possible relationship between antigen-binding affinity and V(H)/V(L) interaction strength, a novel phage display system that can switch two display modes was employed. We focused on the two framework region 2 regions of the HyHEL-10 V(H) and V(L), facing each other at the domain interface, and a combinatorial library was made in which each framework region 2 residue was mixed with that of D1.3, which has a far stronger V(H)/V(L) interaction. The phagemid library, encoding V(H) gene 7 and V(L) amber codon gene 9, was used to transform TG-1 (sup+), and the phages displaying functional variable regions were selected. The selected phages were then used to infect a nonsuppressing strain, and the culture supernatant containing V(H)-displaying phages and soluble V(L) fragment was used to evaluate the V(H)/V(L) interaction strength. The results clearly showed the existence of a key framework region 2 residue (H39) that strongly affects V(H)/V(L) interaction strength, and a marked positive correlation between the antigen-binding affinity and the V(H)/V(L) interaction, especially in the presence of a set of particular V(L) residues. The effect of the H39 mutation on the wild-type variable region was also confirmed by a SPR biosensor as a several-fold increase in antigen-binding affinity owing to an increased association rate, while a slight decrease was observed for the single-chain variable region.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16649995     DOI: 10.1111/j.1742-4658.2006.05232.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  13 in total

1.  Critical contribution of VH-VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10.

Authors:  Takeshi Nakanishi; Kouhei Tsumoto; Akiko Yokota; Hidemasa Kondo; Izumi Kumagai
Journal:  Protein Sci       Date:  2008-02       Impact factor: 6.725

2.  Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.

Authors:  K Reed Clark; Scott T R Walsh
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

3.  Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.

Authors:  Bharat Madan; Baoshan Zhang; Kai Xu; Cara W Chao; Sijy O'Dell; Jacy R Wolfe; Gwo-Yu Chuang; Ahmed S Fahad; Hui Geng; Rui Kong; Mark K Louder; Thuy Duong Nguyen; Reda Rawi; Arne Schön; Zizhang Sheng; Rajani Nimrania; Yiran Wang; Tongqing Zhou; Bob C Lin; Nicole A Doria-Rose; Lawrence Shapiro; Peter D Kwong; Brandon J DeKosky
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-09       Impact factor: 11.205

4.  Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding.

Authors:  Patrick Koenig; Chingwei V Lee; Benjamin T Walters; Vasantharajan Janakiraman; Jeremy Stinson; Thomas W Patapoff; Germaine Fuh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-05       Impact factor: 11.205

5.  CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Authors:  Anke Steinmetz; François Vallée; Christian Beil; Christian Lange; Nicolas Baurin; Jochen Beninga; Cécile Capdevila; Carsten Corvey; Alain Dupuy; Paul Ferrari; Alexey Rak; Peter Wonerow; Jochen Kruip; Vincent Mikol; Ercole Rao
Journal:  MAbs       Date:  2016-03-16       Impact factor: 5.857

6.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Authors:  Robert J Benschop; Chi-Kin Chow; Yu Tian; James Nelson; Barbra Barmettler; Shane Atwell; David Clawson; Qing Chai; Bryan Jones; Jon Fitchett; Stacy Torgerson; Yan Ji; Holly Bina; Ningjie Hu; Mahmoud Ghanem; Joseph Manetta; Victor J Wroblewski; Jirong Lu; Barrett W Allan
Journal:  MAbs       Date:  2019-06-10       Impact factor: 5.857

Review 7.  The structural basis of antibody-antigen recognition.

Authors:  Inbal Sela-Culang; Vered Kunik; Yanay Ofran
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

8.  Identification of nitrated immunoglobulin variable regions in the HIV-infected human brain: implications in HIV infection and immune response.

Authors:  Lerna Uzasci; Mario A Bianchet; Robert J Cotter; Avindra Nath
Journal:  J Proteome Res       Date:  2014-01-30       Impact factor: 4.466

9.  Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.

Authors:  Yi-Fan Zhang; Mitchell Ho
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

10.  Computational Design of an Allosteric Antibody Switch by Deletion and Rescue of a Complex Structural Constellation.

Authors:  Jittasak Khowsathit; Andrea Bazzoli; Hong Cheng; John Karanicolas
Journal:  ACS Cent Sci       Date:  2020-03-11       Impact factor: 14.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.